Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

101. Clinical decision rules for pulmonary embolism in hospitalized patients: a systematic literature review and meta-analysis

Clinical decision rules for pulmonary embolism in hospitalized patients: a systematic literature review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2017 PROSPERO

102. Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment

Optimal strategies for the diagnosis of acute pulmonary embolism: a health technology assessment Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2017 PROSPERO

103. Aplastic anemia and risk of deep vein thrombosis and pulmonary embolism: A nationwide cohort study (Abstract)

Aplastic anemia and risk of deep vein thrombosis and pulmonary embolism: A nationwide cohort study Deep vein thrombosis (DVT) and pulmonary embolism (PE) constitute venous thromboembolism (VTE), which is not fully known in aplastic anemia (AA). Therefore, we investigated the incidence and risk of VTE in AA patients.We conducted a nationwide cohort study to investigate the risk of DVT and PE in patients with AA. We identified patients with newly diagnosed AA as the AA cohort between 2000

2017 EvidenceUpdates

104. Deep Vein Thrombosis in Patients with Pulmonary Embolism: Prevalance, Clinical Significance and Outcome Full Text available with Trip Pro

Deep Vein Thrombosis in Patients with Pulmonary Embolism: Prevalance, Clinical Significance and Outcome Deep venous thrombosis (DVT) and pulmonary embolism (PE) are considered as similar disease entities representing different clinical manifestations. The objectives of this study were: 1) to determine the prevalence and outcome of DVT in patients with PE; 2) to identify additional risk factors for PE-related unfavorable outcome and 30-day all-cause mortality; and 3) to establish the clinical

2016 Vascular specialist international

105. Subacute right heart failure revealing three simultaneous causes of post‐embolic pulmonary hypertension in metastatic dissemination of breast cancer Full Text available with Trip Pro

Subacute right heart failure revealing three simultaneous causes of post‐embolic pulmonary hypertension in metastatic dissemination of breast cancer A 72-year-old woman with history of breast cancer only treated surgically was referred to our department for pulmonary hypertension (PH) suspicion. Echocardiogram revealed elevated right ventricular systolic pressure. Computed tomography (CT) angiogram showed no pulmonary embolism (PE), but lung scan revealed two ventilation-perfusion mismatch (...) areas. Right cardiac catheterization established precapillary PH. Despite treatment with PH specific therapy (sildenafil, ambrisentan, and epoprostenol), her condition worsened rapidly with acute right heart failure (RHF). She died 22 days after admission. Post-mortem microscopic examination showed a rare combination of PH etiologies consistent with metastasis of breast cancer in pulmonary vasculature including the rare pulmonary tumour thrombotic microangiopathy (PTTM).

2016 ESC heart failure

106. Risk stratifying emergency department patients with acute pulmonary embolism: Does the simplified Pulmonary Embolism Severity Index perform as well as the original? (Abstract)

Risk stratifying emergency department patients with acute pulmonary embolism: Does the simplified Pulmonary Embolism Severity Index perform as well as the original? The Pulmonary Embolism Severity Index (PESI) is a validated prognostic score to estimate the 30-day mortality of emergency department (ED) patients with acute pulmonary embolism (PE). A simplified version (sPESI) was derived but has not been as well studied in the U.S. We sought to validate both indices in a community hospital

2016 EvidenceUpdates

107. The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial Full Text available with Trip Pro

The High Risk of Contrast-induced Nephropathy in Patients with Suspected Pulmonary Embolism Despite Three Different Prophylaxis: A Randomized Controlled Trial The objective was to compare the protective effects of N-acetylcysteine (NAC) plus normal saline (NS), sodium bicarbonate (NaHCO3 ) plus NS, and NS alone in the prevention of contrast-induced nephropathy (CIN) after computed tomography pulmonary angiography (CTPA) in emergency patients.This study was planned as a randomized, controlled (...) clinical research. Patients undergoing contrast-enhanced CTPA on suspicion of pulmonary embolism (PE) in the emergency department and with at least one risk factor for development of CIN were included in one of three different prophylaxis groups. The groups received 3 mL/kg intravenous (IV) NAC+NS or NaHCO3 +NS solution or NS alone 1 hour before CTPA and 1 mL/kg IV per hour for a minimum of 6 hours after CTPA. CIN was evaluated as the primary outcome and moderate or severe renal insufficiency

2016 EvidenceUpdates

108. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model Full Text available with Trip Pro

Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model The European Society of Cardiology (ESC) has proposed an updated risk stratification model for death in patients with acute pulmonary embolism based on clinical scores (Pulmonary Embolism Severity Index (PESI) or simplified PESI (sPESI)), right ventricle dysfunction (RVD) and elevated serum troponin (2014 ESC model).We assessed the ability of the 2014 ESC model to predict 30-day (...) death after acute pulmonary embolism. Consecutive patients with symptomatic, confirmed pulmonary embolism included in prospective cohorts were merged in a collaborative database. Patients' risk was classified as high (shock or hypotension), intermediate-high (RVD and elevated troponin), intermediate-low (RVD or increased troponin or none) and low (sPESI 0). Study outcomes were death and pulmonary embolism-related death at 30 days.Among 906 patients (mean±sd age 68±16, 489 females), death

2016 EvidenceUpdates

109. Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol

Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol | CADTH.ca CADTH Document Viewer Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Table of Contents Search this document Addendum to Optimal Strategies (...) for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol October 2016 Ethics Review This protocol was written a priori and will be followed throughout the review process. There are two broad normative questions to consider regarding diagnosis of acute pulmonary embolism (PE): Should we provide diagnosis of acute PE? If yes, which strategies should be provided, and how best should those strategies be provided to diagnose those with acute PE? Both of these questions

2016 CADTH - Optimal Use

110. Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol

Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol | CADTH.ca CADTH Document Viewer Addendum to Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol Table of Contents Search this document Addendum to Optimal Strategies (...) for the Diagnosis of Acute Pulmonary Embolism: A Health Technology Assessment – Project Protocol October 2016 Ethics Review This protocol was written a priori and will be followed throughout the review process. There are two broad normative questions to consider regarding diagnosis of acute pulmonary embolism (PE): Should we provide diagnosis of acute PE? If yes, which strategies should be provided, and how best should those strategies be provided to diagnose those with acute PE? Both of these questions

2016 CADTH - Optimal Use

111. Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. Full Text available with Trip Pro

Prevalence of Pulmonary Embolism among Patients Hospitalized for Syncope. The prevalence of pulmonary embolism among patients hospitalized for syncope is not well documented, and current guidelines pay little attention to a diagnostic workup for pulmonary embolism in these patients.We performed a systematic workup for pulmonary embolism in patients admitted to 11 hospitals in Italy for a first episode of syncope, regardless of whether there were alternative explanations for the syncope (...) . The diagnosis of pulmonary embolism was ruled out in patients who had a low pretest clinical probability, which was defined according to the Wells score, in combination with a negative d-dimer assay. In all other patients, computed tomographic pulmonary angiography or ventilation-perfusion lung scanning was performed.A total of 560 patients (mean age, 76 years) were included in the study. A diagnosis of pulmonary embolism was ruled out in 330 of the 560 patients (58.9%) on the basis of the combination

2016 NEJM

112. Percutaneous mechanical thrombectomy for pulmonary embolism

Percutaneous mechanical thrombectomy for pulmonary embolism Percutaneous mechanical thrombectomy for pulmonary embolism Percutaneous mechanical thrombectomy for pulmonary embolism HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Percutaneous mechanical thrombectomy for pulmonary embolism. Lansdale: HAYES, Inc.. Directory Publication. 2016 (...) alone has failed or is contraindicated. However, the technology is invasive and relatively new, warranting assessment of effectiveness, safety, and the performance of the different commercially available devices. Relevant Questions: For patients with pulmonary embolism (PE), is PMT effective for eliminating thromboses and emboli, restoring blood flow and vascular function, and preventing damage to tissues and organs? Are PMT devices safe? How do PMT devices compare with other standard treatments

2016 Health Technology Assessment (HTA) Database.

113. Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Full Text available with Trip Pro

Treatment of acute pulmonary embolism with dabigatran versus warfarin. A pooled analysis of data from RE-COVER and RE-COVER II Dabigatran was non-inferior to warfarin for prevention of recurrent venous thromboembolism (VTE), and dabigatran had a lower rate of bleeding compared with warfarin in two large-scale randomised trials, RE-COVER and RE-COVER II. In this study, we investigate the efficacy and safety of dabigatran versus warfarin according to the index event that qualified the patient (...) for enrollment, either symptomatic pulmonary embolism (PE) with or without deep-vein thrombosis (DVT), or DVT alone. We then analyse the anticoagulant effect of dabigatran vs warfarin on patients enrolled with PE. The pooled dataset for the efficacy analysis consisted of 2553 and 2554 patients who were randomised to dabigatran and warfarin, respectively. Recurrent VTE/VTE-related death during the study period and additional 30-day follow-up occurred in 2.7 % of all patients on dabigatran and in 2.4

2016 EvidenceUpdates Controlled trial quality: uncertain

114. Diagnostic characteristics of lower limb venous compression ultrasonography in suspected pulmonary embolism: a meta-analysis Full Text available with Trip Pro

Diagnostic characteristics of lower limb venous compression ultrasonography in suspected pulmonary embolism: a meta-analysis Essentials Lower limb ultrasonography (CUS) could be useful in suspected pulmonary embolism (PE). We performed a metaanalysis on the diagnostic characteristics of CUS in suspected PE. With a sensitivity of 41%, proximal CUS would be positive in one of every 7.3 patients. Complete CUS has a higher sensitivity but specificity for PE is too low to use it in suspected (...) PE.Background Diagnosis of pulmonary embolism (PE) is commonly based on D-dimer measurement and computed tomography (CT) angiography. Lower limb vein compression ultrasonography (CUS) for diagnosing deep vein thrombosis may be of interest in patients with suspected PE. Objectives We aimed to summarize the data on the diagnostic characteristics of CUS in suspected PE patients. Patients/Methods We conducted a literature review by using PUBMED and EMBASE and included 15 prospective studies in which CUS

2016 EvidenceUpdates

115. D-dimer test for excluding the diagnosis of pulmonary embolism. Full Text available with Trip Pro

D-dimer test for excluding the diagnosis of pulmonary embolism. Pulmonary embolism (PE) can occur when a thrombus (blood clot) travels through the veins and lodges in the arteries of the lungs, producing an obstruction. People who are thought to be at risk include those with cancer, people who have had a recent surgical procedure or have experienced long periods of immobilisation and women who are pregnant. The clinical presentation can vary, but unexplained respiratory symptoms (...) recruitment.We searched 13 databases from conception until December 2013. We cross-checked the reference lists of relevant studies.Two review authors independently applied exclusion criteria to full papers and resolved disagreements by discussion.We included cross-sectional studies of D-dimer in which ventilation/perfusion (V/Q) scintigraphy, computerised tomography pulmonary angiography (CTPA), selective pulmonary angiography and magnetic resonance pulmonary angiography (MRPA) were used as the reference

2016 Cochrane

116. Optimal Diagnosis for Suspected Acute Pulmonary Embolism

Optimal Diagnosis for Suspected Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: March 1, 2018 Project Number: OP0528-000 Product Line: Research Type: Other Diagnostics Result type: Report Pulmonary embolism (PE) is a blockage of one of the arteries in the lung, frequently (...) as potential environmental impact were also addressed. Tags blood, decision support techniques, diagnostic tests, echocardiography, fibrin fibrinogen degradation products, magnetic resonance imaging, pet scan, perfusion imaging, positron-emission tomography, pulmonary embolism, radionuclide imaging, spect, tomography, ultrasonography, venous thromboembolism, ct scan, imaging, mri, respiratory, ultrasound, CT angiography, CT pulmonary angiography, CTPA, Emission-Computed, Geneva, MRIs, PERC, PET, PET-CT

2016 CADTH - Optimal Use

117. Optimal Imaging for Suspected Acute Pulmonary Embolism

Optimal Imaging for Suspected Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism | CADTH.ca Find the information you need Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Optimal Strategies for the Diagnosis of Acute Pulmonary Embolism Published on: March 1, 2018 Project Number: OP0528-000 Product Line: Research Type: Other Diagnostics Result type: Report Pulmonary embolism (PE) is a blockage of one of the arteries in the lung, frequently (...) as potential environmental impact were also addressed. Tags blood, decision support techniques, diagnostic tests, echocardiography, fibrin fibrinogen degradation products, magnetic resonance imaging, pet scan, perfusion imaging, positron-emission tomography, pulmonary embolism, radionuclide imaging, spect, tomography, ultrasonography, venous thromboembolism, ct scan, imaging, mri, respiratory, ultrasound, CT angiography, CT pulmonary angiography, CTPA, Emission-Computed, Geneva, MRIs, PERC, PET, PET-CT

2016 CADTH - Optimal Use

118. On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism (Abstract)

On the necessity of new decision-making methods for cancer-associated, symptomatic, pulmonary embolism Acute symptomatic pulmonary embolism (PE) varies in its clinical manifestations in patients with cancer and entails specific issues. The objective is to assess the performance of five scores (PESI, sPESI, GPS, POMPE, and RIETE) and a clinical decision rule to predict 30-day mortality.This is an ambispective, observational, multicenter study that collected episodes of PE in patients with cancer

2016 EvidenceUpdates

119. Deep vein thrombosis and pulmonary embolism. (Abstract)

Deep vein thrombosis and pulmonary embolism. Deep vein thrombosis and pulmonary embolism, collectively referred to as venous thromboembolism, constitute a major global burden of disease. The diagnostic work-up of suspected deep vein thrombosis or pulmonary embolism includes the sequential application of a clinical decision rule and D-dimer testing. Imaging and anticoagulation can be safely withheld in patients who are unlikely to have venous thromboembolism and have a normal D-dimer. All other (...) patients should undergo ultrasonography in case of suspected deep vein thrombosis and CT in case of suspected pulmonary embolism. Direct oral anticoagulants are first-line treatment options for venous thromboembolism because they are associated with a lower risk of bleeding than vitamin K antagonists and are easier to use. Use of thrombolysis should be limited to pulmonary embolism associated with haemodynamic instability. Anticoagulant treatment should be continued for at least 3 months to prevent

2016 Lancet

120. Comparison of risk assessment strategies for not-high-risk pulmonary embolism Full Text available with Trip Pro

Comparison of risk assessment strategies for not-high-risk pulmonary embolism We compared the prognostic performance of the 2014 European Society of Cardiology (ESC) risk stratification algorithm with the previous 2008 ESC algorithm, the Bova score and the modified FAST score (based on a positive heart-type fatty acid-binding protein (H-FABP) test, syncope and tachycardia, modified using high-sensitivity troponin T instead of H-FABP) in 388 normotensive pulmonary embolism patients included (...) in a single-centre cohort study.Overall, 25 patients (6.4%) had an adverse 30-day outcome. Regardless of the score or algorithm used, the rate of an adverse outcome was highest in the intermediate-high-risk classes, while all patients classified as low-risk had a favourable outcome (no pulmonary embolism-related deaths, 0-1.4% adverse outcome). The area under the curve for predicting an adverse outcome was higher for the 2014 ESC algorithm (0.76, 95% CI 0.68-0.84) compared with the 2008 ESC algorithm

2016 EvidenceUpdates